Health Care & Life Sciences » Biotechnology | Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc. | Mutual Funds

Mutual Funds that own Brainstorm Cell Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard Total Stock Market Index Fund
412,248
1.99%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
238,368
1.14%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
60,624
0.28%
0
0%
07/31/2018
iShares Micro Cap ETF
47,328
0.23%
0
0.02%
09/06/2018
32,403
0.16%
0
0.24%
09/06/2018
Fidelity Nasdaq Composite Index
29,253
0.14%
0
0%
07/31/2018
Vanguard Institutional Total Stock Market Index Fund
20,475
0.1%
0
0%
07/31/2018
Vanguard Balanced Index Fund
16,566
0.08%
0
0%
07/31/2018
Fidelity Spartan Total Market Index Fund
15,396
0.07%
0
0%
07/31/2018
iShares Core S&P Total US Stock Market ETF
9,563
0.05%
0
0%
09/06/2018

About Brainstorm Cell Therapeutics

View Profile
Address
1325 Avenue of Americas
New York New Jersey 10019
United States
Employees -
Website http://www.brainstorm-cell.com
Updated 07/08/2019
Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.